Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Scutellaria decoction is a Traditional Chinese Medicine (TCM) herbal formulation based on the classical Huangqin Tang. It is being evaluated as an adjuvant therapy to standard chemotherapy (such as 5-fluorouracil and irinotecan) for patients with metastatic colorectal cancer, specifically those presenting with a damp-heat syndrome pattern. The decoction typically contains *Scutellaria baicalensis* as its primary ingredient, which is known for its anti-inflammatory and potential anti-tumor properties. In the context of oncology, it is used to improve quality of life, reduce chemotherapy-induced gastrointestinal toxicity (such as diarrhea), and potentially enhance the efficacy of conventional treatments by modulating inflammatory pathways and the gut environment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified Scutellaria decoction.